从基金十大重仓股角度 1月12日，金域医学涨5.17%，截至发稿，报35.40元/股，成交4136.12万元，换手率0.25%，总市值 163.99亿元。 资料显示，广州金域医学检验集团股份有限公司位于广东省广州市国际生物岛螺旋三路10号，成立日期 2006年5月26日，上市日期2017年9月8日，公司主营业务涉及为全国超过23,000家各类医疗机构提供包 括理化质谱检验、基因组检验、病理诊断、生化发光检验、免疫学检验、其他综合检验等六大类合计近 80类检验技术,近3,200项检验项目的外包及科研技术服务。主营业务收入构成为：医学诊断服务 91.20%，销售诊断6.45%，其他1.47%，冷链物流服务0.62%，健康体检业务0.27%。 长城消费增值混合A（200006）成立日期2006年4月6日，最新规模5.16亿。今年以来收益17.29%，同类 排名26/9012；近一年收益40.7%，同类排名3084/8157；成立以来收益300.18%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考， ...

截至9月30日，金域医学股东户数4.17万，较上期减少1.60%；人均流通股11042股，较上期增加1.62%。 2025年1月-9月，金域医学实现营业收入45.38亿元，同比减少19.23%；归母净利润-7960.95万元，同比 减少184.84%。 金域医学今年以来股价涨4.83%，近5个交易日涨6.52%，近20日涨4.17%，近60日涨2.41%。 资料显示，广州金域医学检验集团股份有限公司位于广东省广州市国际生物岛螺旋三路10号，成立日期 2006年5月26日，上市日期2017年9月8日，公司主营业务涉及为全国超过23,000家各类医疗机构提供包 括理化质谱检验、基因组检验、病理诊断、生化发光检验、免疫学检验、其他综合检验等六大类合计近 80类检验技术,近3,200项检验项目的外包及科研技术服务。主营业务收入构成为：医学诊断服务 91.20%，销售诊断6.45%，其他1.47%，冷链物流服务0.62%，健康体检业务0.27%。 分红方面，金域医学A股上市后累计派现25.45亿元。近三年，累计派现16.47亿元。 资金流向方面，主力资金净流出1643.23万元，特大单买入0.00元，占比0.00%，卖 ...

Core Viewpoint - The stock of Kingmed Diagnostics has experienced fluctuations, with a recent decline of 2.00% and a year-to-date increase of 12.08%, indicating volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion yuan, a year-on-year decrease of 19.23%, and a net profit attributable to shareholders of -796.095 million yuan, representing a significant decline of 184.84% [2]. - The company has distributed a total of 2.545 billion yuan in dividends since its A-share listing, with 1.647 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Kingmed Diagnostics was 41,700, a decrease of 1.60% from the previous period, with an average of 11,042 circulating shares per shareholder, an increase of 1.62% [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 35.5057 million shares, which is a reduction of 2.8676 million shares from the previous period [3]. Market Activity - The stock has seen a trading volume of 73.3667 million yuan with a turnover rate of 0.53%, and the total market capitalization stands at 13.838 billion yuan [1]. - Kingmed Diagnostics has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on February 7 [1].

11月18日，金域医学盘中上涨2.05%，截至13:03，报30.80元/股，成交8056.58万元，换手率0.58%，总 市值142.68亿元。 资金流向方面，主力资金净流入257.97万元，特大单买入151.44万元，占比1.88%，卖出0.00元，占比 0.00%；大单买入1425.31万元，占比17.69%，卖出1318.78万元，占比16.37%。 金域医学今年以来股价涨15.57%，近5个交易日涨2.98%，近20日涨7.77%，近60日跌0.77%。 今年以来金域医学已经1次登上龙虎榜，最近一次登上龙虎榜为2月7日。 资料显示，广州金域医学检验集团股份有限公司位于广东省广州市国际生物岛螺旋三路10号，成立日期 2006年5月26日，上市日期2017年9月8日，公司主营业务涉及为全国超过23,000家各类医疗机构提供包 括理化质谱检验、基因组检验、病理诊断、生化发光检验、免疫学检验、其他综合检验等六大类合计近 80类检验技术,近3,200项检验项目的外包及科研技术服务。主营业务收入构成为：医学诊断服务 91.20%，销售诊断6.45%，其他1.47%，冷链物流服务0.62%，健康体检业务0.27% ...

Core Viewpoint - The stock of Guangzhou Kingmed Diagnostics Group Co., Ltd. has shown a positive trend, with a year-to-date increase of 15.38% and a recent uptick in trading activity, indicating potential investor interest and market confidence [1][2]. Company Overview - Guangzhou Kingmed Diagnostics Group Co., Ltd. was established on May 26, 2006, and went public on September 8, 2017. The company provides a wide range of diagnostic services to over 23,000 medical institutions across China, covering nearly 80 types of testing technologies and approximately 3,200 testing items [2]. - The company's revenue composition includes 91.20% from medical diagnostic services, 6.45% from sales of diagnostics, and smaller contributions from other services [2]. Financial Performance - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion yuan, reflecting a year-on-year decrease of 19.23%. The net profit attributable to shareholders was -796.095 million yuan, a significant decline of 184.84% compared to the previous year [2]. - The company has distributed a total of 2.545 billion yuan in dividends since its A-share listing, with 1.647 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Kingmed Diagnostics was 41,700, a decrease of 1.60% from the previous period. The average number of circulating shares per shareholder increased by 1.62% to 11,042 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 35.5057 million shares, which is a reduction of 2.8676 million shares from the previous period [3].

Group 1 - The core point of the news is that Kingmed Diagnostics has experienced a significant decline in stock price, dropping 5.02% on September 23, with a total market value of 13.32 billion yuan and a cumulative decline of 7.15% over six consecutive days [1] - Kingmed Diagnostics, established on May 26, 2006, and listed on September 8, 2017, provides a wide range of medical testing services to over 23,000 medical institutions across China, including nearly 80 types of testing technologies and approximately 3,200 testing projects [1] - The company's main business revenue composition includes: medical diagnostic services at 91.20%, sales of diagnostics at 6.45%, other services at 1.47%, cold chain logistics at 0.62%, and health check-up services at 0.27% [1] Group 2 - From the perspective of fund holdings, one fund under Chuangjin Hexin has a significant position in Kingmed Diagnostics, with 311,000 shares held, accounting for 4.5% of the fund's net value, ranking as the eighth largest holding [2] - The fund has incurred a floating loss of approximately 472,700 yuan today and a total floating loss of 724,600 yuan during the six-day decline [2] - The Chuangjin Hexin Medical Consumption Stock A fund, established on December 3, 2020, has a current scale of 173 million yuan, with a year-to-date return of 3.63% and a one-year return of 17.93% [2]

Core Viewpoint - Kingmed Diagnostics has experienced a continuous decline in stock price, with a total drop of 7.11% over the past six days, indicating potential concerns among investors regarding the company's performance and market conditions [1]. Company Overview - Kingmed Diagnostics, established on May 26, 2006, and listed on September 8, 2017, is located in Guangzhou, Guangdong Province. The company provides a wide range of diagnostic services to over 23,000 medical institutions across China, offering nearly 80 types of testing technologies and approximately 3,200 testing projects [1]. - The main revenue composition of Kingmed Diagnostics includes: 91.20% from medical diagnostic services, 6.45% from sales of diagnostics, 1.47% from other services, 0.62% from cold chain logistics, and 0.27% from health check-up services [1]. Shareholder Insights - Among the top shareholders of Kingmed Diagnostics, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 84,000 shares in the second quarter, now holding 9.13 million shares, which accounts for 1.98% of the circulating shares. The estimated floating loss today is approximately 3.74 million yuan, with a total floating loss of 21.18 million yuan during the six-day decline [2]. - The Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 26.15 billion yuan. Year-to-date returns are 18.89%, ranking 2640 out of 4222 in its category, while the one-year return is 42.38%, ranking 2435 out of 3813 [2].